NASDAQ:GBT Global Blood Therapeutics - GBT Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Global Blood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$68.49▼$68.4950-Day Range$68.07▼$68.4952-Week Range$21.65▼$73.02Volume74 shsAverage Volume2.07 million shsMarket Capitalization$4.62 billionP/E RatioN/ADividend YieldN/APrice Target$65.42 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Global Blood Therapeutics MarketRank™ ForecastAnalyst RatingHold2.21 Rating ScoreUpside/Downside4.5% Downside$65.42 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.95Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.71) to ($3.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.01 out of 5 starsMedical Sector1037th out of 1,049 stocksPharmaceutical Preparations Industry505th out of 514 stocks 1.1 Analyst's Opinion Consensus RatingGlobal Blood Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 3 buy ratings, 11 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.42, Global Blood Therapeutics has a forecasted downside of 4.5% from its current price of $68.49.Amount of Analyst CoverageGlobal Blood Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GBT. Previous Next 0.0 Dividend Strength Dividend YieldGlobal Blood Therapeutics does not currently pay a dividend.Dividend GrowthGlobal Blood Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlobal Blood Therapeutics has received a 54.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other hematological medication (B06)", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Global Blood Therapeutics is -1.95. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Global Blood Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Global Blood Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Global Blood Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of Global Blood Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Global Blood Therapeutics are expected to grow in the coming year, from ($4.71) to ($3.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Global Blood Therapeutics is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Global Blood Therapeutics is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlobal Blood Therapeutics has a P/B Ratio of 22.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Global Blood Therapeutics (NASDAQ:GBT) StockGlobal Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Read More Receive GBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GBT Stock News HeadlinesJanuary 25, 2023 | finance.yahoo.comGBT Filed a Non-Provisional Patent for Predictive Technology, to Design and Manufacture Three-Dimensional, Multi-Planar SemiconductorsJanuary 14, 2023 | finance.yahoo.comGlobal Head And Neck Cancer Therapeutics Market Report 2022: Sector to Reach $2.5 Billion by 2028 at a 12.3% CAGRJanuary 30, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.January 13, 2023 | marketwatch.comThe Global Plasma Protein Therapeutics Market is expected to grow at CAGR of 5.03% during 2023-2027January 12, 2023 | marketwatch.comAnemia Drugs Market Growth, Size, Share, Opportunities, Industry Analysis and Forecast 2023 To 2028January 12, 2023 | nz.finance.yahoo.comGBT’s Wireless, Motion Detection and Imaging, Continuation Patent Application Received a Notice of PublicationJanuary 10, 2023 | marketwatch.comSickle-cell Anemia Therapeutics Market Size 2023 Research Report Analysis by Manufactures, Types, Application, Trends and Forecast to 2026January 10, 2023 | nz.finance.yahoo.comGBT's Facial and Body Recognition Patent Application is GrantedJanuary 30, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.January 10, 2023 | thestreet.comGlobal Blood Valuation Gives Goldman Analyst PauseJanuary 9, 2023 | benzinga.comHeart Failure Market Report (2022 to 2030) – Tenax Therapeutics, Novartis Ag, Bayer Ag, Bristol-Myers Squibb, Eli Lilly And CompanyJanuary 5, 2023 | benzinga.comThe Global Intracranial Hemorrhage Devices Market to Exhibit Growth at a CAGR of 6.65% by 2027 | DelveInsightJanuary 5, 2023 | finance.yahoo.comGlobal Blood Plasma Derivatives Market to Reach $72.5 Billion by 2028 at a CAGR of 9.3%January 5, 2023 | thestreet.comGlobal Blood Therapeutics (GBT) Stock Surges on Promising Sickle Cell Drug ResultsJanuary 4, 2023 | marketwatch.comGlobal Autoimmune Hemolytic Anemia Therapeutics Market (Latest Report) is booming in near Future 2023-2029| 121 Pages ReportJanuary 4, 2023 | marketwatch.comComplete Blood Count (CBC) Market (New Report) 2023 Is Flourishing Around the World by 2029 | 110 Pages ReportJanuary 4, 2023 | nz.finance.yahoo.comGBT’s 3D, Multiplanar IC received a Notice of Allowance in KoreaJanuary 4, 2023 | thestreet.comGlobal Blood Shows Extended, Safe Treatment Effect for Sickle Cell Disease DrugDecember 25, 2022 | thestreet.comGlobal Blood Bolsters Sickle Cell Drug With More Patient DataDecember 21, 2022 | it.tmcnet.comGBT received a noticed of publication for its Integrated Circuit's Geometrical Design Rule Automatic Correction patentDecember 19, 2022 | marketwatch.comBlood Bank Management Software Market, Leading Players, Growth and Business Opportunities by 2029December 13, 2022 | benzinga.comAmex GBT Chief Revenue Officer to step down after 34-year careerDecember 12, 2022 | marketwatch.comSafe Blood Collection Needle Market to Witness A Pronounce Growth During 2023-2028 | 96 Pages ReportDecember 9, 2022 | marketwatch.comBlood Plasma Products Market 2023 To Garner Overwhelming Hike In Revenues by 2026December 8, 2022 | marketwatch.comBlood-Brain Barrier Transport Drugs Market 2022 Report Offers Key Futuristic Top Trends And Competitive Landscape By 2028December 7, 2022 | benzinga.comGlobal Bacteriophage Therapy Market Report 2022: Sector Set for Significant Growth With Over $1 Billion in Public and Private InvestmentsDecember 5, 2022 | marketwatch.comPeptide Based Metabolic Disorders Therapeutics Market Is Likely to Experience a Strong Growth During 2023-2028 with Top Countries DataSee More Headlines Receive GBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GBT Company Calendar Last Earnings11/04/2021Today1/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GBT CUSIPN/A CIK1629137 Webwww.gbt.com Phone(650) 741-7700FaxN/AEmployees457Year FoundedN/APrice Target and Rating Average Stock Price Forecast$65.42 High Stock Price Forecast$75.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside-4.5%Consensus RatingHold Rating Score (0-4)2.21 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-303,090,000.00 Net Margins-137.30% Pretax Margin-137.01% Return on Equity-170.37% Return on Assets-39.24% Debt Debt-to-Equity Ratio4.92 Current Ratio6.88 Quick Ratio6.17 Sales & Book Value Annual Sales$194.75 million Price / Sales23.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book22.46Miscellaneous Outstanding Shares67,476,000Free Float64,170,000Market Cap$4.62 billion OptionableOptionable Beta0.45 Key ExecutivesDr. Ted W. Love M.D. (Age 63)Pres, CEO & Director Comp: $1.06MMr. Jeffrey S. Farrow (Age 60)CFO & Principal Accounting Officer Comp: $672.67kMs. Jung E. Choi (Age 52)Chief Bus. & Strategy Officer Comp: $645kMr. David L. Johnson (Age 53)Chief Commercial Officer Comp: $661.5kDr. Kim Smith-Whitley M.D. (Age 61)Exec. VP and Head of R&D Comp: $654kDr. David R. PhillipsFounder & AdvisorDr. Matthew P. Jacobson Ph.D.Founder & AdvisorDr. Andrej Sali Ph.D.Founder & AdvisorMs. Nazila Habibizad (Age 59)Exec. VP of Operations Stephanie YaoSr. Director of Corp. Communications & Investor RelationsMore ExecutivesKey CompetitorsAlkermesNASDAQ:ALKSIntra-Cellular TherapiesNASDAQ:ITCIZai LabNASDAQ:ZLABPerrigoNYSE:PRGOPrometheus BiosciencesNASDAQ:RXDXView All CompetitorsInsiders & InstitutionsFNY Investment Advisers LLCSold 23 shares on 1/10/2023Ownership: 0.000%Bank of New York Mellon CorpBought 18,594 shares on 12/8/2022Ownership: 0.404%Mint Tower Capital Management B.V.Bought 790 shares on 11/22/2022Ownership: 0.001%California State Teachers Retirement SystemSold 404 shares on 11/21/2022Ownership: 0.117%Parallax Volatility Advisers L.P.Bought 5,221 shares on 11/21/2022Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions GBT Stock - Frequently Asked Questions Should I buy or sell Global Blood Therapeutics stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 11 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GBT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBT, but not buy additional shares or sell existing shares. View GBT analyst ratings or view top-rated stocks. What is Global Blood Therapeutics' stock price forecast for 2023? 14 Wall Street research analysts have issued 1-year price objectives for Global Blood Therapeutics' stock. Their GBT share price forecasts range from $31.00 to $75.00. On average, they predict the company's share price to reach $65.42 in the next twelve months. This suggests that the stock has a possible downside of 4.5%. View analysts price targets for GBT or view top-rated stocks among Wall Street analysts. How were Global Blood Therapeutics' earnings last quarter? Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by $0.03. The company had revenue of $52.05 million for the quarter, compared to the consensus estimate of $53.69 million. Global Blood Therapeutics had a negative net margin of 137.30% and a negative trailing twelve-month return on equity of 170.37%. The firm's revenue for the quarter was up 41.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.97) EPS. What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO? 20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend. What other stocks do shareholders of Global Blood Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ). When did Global Blood Therapeutics IPO? (GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers. What is Global Blood Therapeutics' stock symbol? Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT." Who are Global Blood Therapeutics' major shareholders? Global Blood Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FNY Investment Advisers LLC (0.00%). Insiders that own company stock include Dawn Svoronos, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Nazila Habibizad, Philip A Pizzo, Scott W Morrison, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown. View institutional ownership trends. What is Global Blood Therapeutics' stock price today? One share of GBT stock can currently be purchased for approximately $68.49. How much money does Global Blood Therapeutics make? Global Blood Therapeutics (NASDAQ:GBT) has a market capitalization of $4.62 billion and generates $194.75 million in revenue each year. The company earns $-303,090,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis. How many employees does Global Blood Therapeutics have? The company employs 457 workers across the globe. How can I contact Global Blood Therapeutics? Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.gbt.com. The company can be reached via phone at (650) 741-7700 or via email at investor@gbt.com. This page (NASDAQ:GBT) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.